ENTITY
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy
Forta Healthcare: $55M Series A to Scale AI-Driven Parent-Led Autism Therapy and Expand Services
Forta, Child, Applied Behavior Analysis
Lilly’s Donanemab Poised for FDA Decision amid Embraced Alzheimer’s Disease Competition
Alzheimer’s Disease, Donanemab, United States Food and Drug Administration, Lilly’s